Protein-protein interactions mediate most physiological and disease processes. Helix-constrained peptides potently mimic or inhibit these interactions by making multiple contacts over large surface areas. However, despite high affinities, they typically have short lifetimes bound to the protein. Here we insert both a helix-inducing constraint and an adjacent electrophile into the native peptide ligand BIM to target the oncogenic protein Bcl2A1. The modified BIM peptide bonds covalently and irreversibly to one cysteine within the helix-binding groove of Bcl2A1, but not to two other exposed cysteines on its surface, and shows no covalent bonding to other Bcl2 proteins. It also penetrates cell membranes and bonds covalently to Bcl2A1 inside cells. This innovative approach to increasing receptor residence time of helical peptides demonstrates the potential to selectively silence a PPI inside cells, with selectivity over other nucleophilic sites on proteins.
Intracellular protein-protein interactions (PPIs) are emerging as the most prevalent biological targets for developing new therapeutics. However, most PPIs involve large, shallow, solvent-exposed, polar surfaces without hydrophobic pockets for accommodating small drug-like compounds. Conventional small organic molecule drug discovery has consequently met with little success to date in producing effective and selective modulators of PPIs. 1 On the other hand, peptides present larger protein-like surfaces 2 and, especially when helix-constrained, have shown promise for modulating PPIs inside cells due to enhanced potency, and some, albeit limited, cell permeability and metabolic stability. [3] [4] [5] [6] [7] [8] [9] Another drawback of injectable peptide drugs 10 is that they often have fast off-rates from their target protein, 11 contributing to only moderate cell activity at µM concentrations. For some small molecule drugs, protein ing and duration of drug action have been increased by incorporating an electrophile, producing irreversible inhibitors of enzymes like kinases. [12] [13] [14] Historically, this approach has been accompanied by off-target side effects due to indiscriminate bonding of the electrophile to endogenous nucleophiles. 12 However, in recent years the quest for longer acting drugs with greater clinical efficacy has led to a resurgence of covalent drugs, especially with more discriminating and milder electrophiles like acrylamides with fewer off-target side effects. [15] [16] [17] [18] There are now 42 approved covalent drugs (3 of 27 approved drugs in 2013 were covalent inhibitors). 18 Recently, we outlined a computational and design approach to finding proteins bearing a nucleophile (e.g. Cys or Lys) located in or nearby the binding site of endogenous helical ligands, and to designing synthetic helix-constrained peptides bearing an electrophile appropriately positioned to make an optimal covalent bond. 19 This approach is validated here, extending the scope of covalent drugs to peptidomimetics that can modulate PPIs. Figure 1 . PPI targeting by covalent helical peptides. A. Bim peptide (green) bound to Bcl2A1 protein (gray) where a Cys residue (yellow) is close to helix-binding site. Bcl2A1 also has two other surface Cys residues (PDB: 2VM6). B. Sequence of helixconstrained peptide 1 (BimSAHB A , full structure in Fig. S1 ) with an indole of Trp2 (green) replaced by an acrylamide electrophile (red). 19 C. Distance (3.8 Å) between S of Cys55 (yellow) in Bcl2A1 and β-carbon of Bim Trp2 (green) can fit a small electrophile. D. Helix-constrained peptide (green) first binds noncovalently to protein (gray), then electrophile (red) in peptide bonds covalently to nucleophilic Cys (yellow) in protein.
We sought to increase the residence time on an oncogenic target protein Bcl2A1 20 (Fig. 1A ) of a helix-constrained pep-
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tide Bim 21, 22 (Fig. 1B) by innovatively 19 introducing an electrophilic warhead positioned carefully to form a putative covalent bond to sulfur in Cys55 in the target protein ( Fig. 1B, 1C ).
Bcl2A1 is amplified in ∼30% of melanomas and is necessary for melanoma growth, with suppression of this gene promoting apoptosis. 23 Bcl2A1 is also overexpressed in other types of cancer, including leukemias and lymphomas, and induces resistance to chemotherapeutic drugs. [23] [24] [25] [26] [27] Bcl2A1 binds to BH3only proteins, including pro-apoptotic BimBH3 helix. 28 Trp2 of BimBH3 peptide is close to Cys55 in Bcl2A1 (Fig. 1A, 1C ), enabling potential insertion of an electrophile to make a covalent adduct. 20 The idea is that helix-constrained BimBH3 peptide 1 (BimSAHB A , Fig. 1B) forms an initial non-covalent and selective interaction with Bcl2 proteins, followed by subsequent slower and more specific covalent bonding of a mild electrophile, such as acrylamide, to the nearby nucleophilic sulfur of Cys55 in the BH3-binding site of Bcl2A1, but not in other Bcl2 proteins. Acrylamides are Michael acceptors previously employed as physiological compatible electrophiles in covalent inhibitors, including Ibrutinib, an FDA-approved drug acting on B-cell tumours. 18 An analogue of 1, with diaminopropionic acid (Dap) replacing Trp2, was synthesized on solid phase using on-resin ring closing metathesis to create the helix-inducing macrocyclic constraint. 21 Acrylamide was then attached to the Dap sidechain affording 2 ( Fig. 2 and Fig. S1 ), which showed similar α-helicity to peptide 1 (Fig. S1 ). Figure S1 ).
Reaction of the electrophilic peptide 2 with the Bcl2A1 protein ( Fig. 3 ) was investigated at different concentrations, times, pH and temperature. Formation of the covalent protein conjugate 3 was first assessed in a dose-dependent manner at pH 7.2 using SDS-PAGE gels ( Fig. 3B) , producing a single higher molecular weight band (>90%) from a ratio as low as 2:1 (peptide:protein) after 2h at 22°C. Unsurprisingly, the control peptide (BimSAHB A , 1) did not produce this higher molecular weight adduct ( Fig. 3B ) since it has no electrophile.
Bcl2A1 has three free Cys residues, so it was necessary to confirm that the electrophilic peptide 2 covalently bound only to the target Cys55 and not also to one or more of the other two surface-exposed Cys residues. Trypsin digestion of the single covalent adduct band on the SDS-PAGE gel (Fig. 4A ), coupled with MS/MS spectral analysis, showed a 1:1 complex with an expected fragmentation for a single adduct covalently and specifically bound to Cys55 of Bcl2A1 ( Fig. 4A ). Furthermore, we investigated possible reactions of 2 with other proteins of the Bcl2 family ( Fig. 4B ) and with off-target nucleophiles. As anticipated, SDS-PAGE gel analysis showed no covalent reaction of 2 to other Bcl2 proteins (Mcl-1, Bcl-2, Bcl-xL), which do not contain a Cys within the BH3 binding site. Exposed Cys residues in other regions of these other Bcl2 proteins also did not bond covalently to 2 (Fig. 4B ). Peptide 2 remained intact and mostly unaffected in 1 mM dithiothreitol over several hours ( Fig. S2 ) and displayed similar human serum stability as peptide 1, indicating no significant reaction of the electrophile with plasma proteins (Fig. S3 ). 
The profile of binding of electrophilic peptide 2 to Bcl2A1 was assessed by fluorescence polarization (FP) experiments. Binding to Bcl2A1 was measured in competition with a known fluorescent ligand Bid (FBID, FITC-βA-DIIRNIARHLAQVGDSMRSI-NH2) that also binds to the same BH3-binding site of the protein. 29 Peptide 2 was found to inhibit Bcl2A1-FBID binding (t 1/2 28 min) with complete inhibition by ~90 min (Fig. 5A ). At the same Bcl2A1:FBID ratio (50:1) where the ligand is saturated with protein, addition of non-electrophilic peptide 1 did not significantly interfere with the FP signal, suggesting that over this time period peptide 2 bonds covalently to Bcl2A1. The ligand efficiency was compared for 1 versus 2 in a competitive binding assay against the Bcl2A1-FBID complex. A ratio of Bcl2A1:FBID = 3:1 was maintained to allow measurable fluorescence. Figure 5B shows that 2 was 13-fold more potent in blocking Bcl2A1 interaction with FBID than the reversible peptide 1 (IC 50 after 2h incubation: 8.5 nM (2) vs 110 nM (1)). This translated to an apparent Ki <0.1 nM for 2 and 32 nM for 1 (after 2h). Reversible (Fig. 5C ) versus irreversible (Fig. 5D ) binding of Bcl2A1 to 1 versus 2, respectively, was demonstrated by titration binding curves in the presence of FBID. A two-fold serial dilution of Bcl2A1 (ranging from 250 to 0.25 nM concentration) was pre-incubated with each peptide at various protein:peptide ratios (Fig. 5C, 5D ). After 1h, the resulting Bcl2A1:peptide complex was combined with FBID and FP recorded. Peptide 1 did not significantly affect maximum fluo-rescence measured at high Bcl2A1 concentrations without peptide (Fig. 5C ), consistent with a reversible inhibitor. In contrast, the covalent inhibitor 2 reduced the amount of FBID binding and fluorescence in a dose-dependent manner (Fig.  5D ). Full inhibition of Bcl2A1-FBID formation was observed after pretreatment with ≥ 2-fold 2 for 2h.
Four electrophiles (acrylamide, chloroacetamide, propiolamide, cyclopentene-carboxamide) were compared for covalent bonding to Bcl2A1. Incorporated into position 2 of the stapled Bim (via the side-chain of a Dap residue) gave peptides 2, 5, 6 and 7 respectively (Fig. 6) . Additionally, peptide 8 was prepared by direct coupling to β-chloroalanine at position 2. 30 Mass spectra (Fig. 6 ) showed different reactions with Bcl2A1, the more powerful electrophiles (5, 6) adding multiple times to Bcl2A1 instead of the 1:1 complex observed for 2. On the other hand, electrophiles in 7 and 8 did not bond covalently to Bcl2A1 under the same conditions, possibly due to unfavorable positioning of the electrophile (8) or reduced electrophilicity (7) . Neither the acrylamide electrophile, nor an appended fluorophore ( Fig. 7A) , compromised the cell-penetrating capacity of the stapled Bim scaffold according to flow cytometry analysis (Fig. 7B ). Live cell confocal microscopy of U937 lymphoma cells incubated with FITC-derived peptide 2 (9, Fig. 7A ) established cellular uptake of the electrophilic peptide and its trafficking to mitochondria, where Bcl2 proteins are predominantly localized (Fig. 7A) . 21, 22 Next, we investigated whether peptide 2 also bonds covalently to Bcl2A1 endogenously expressed in U937 lymphoma cells (Fig. 7C ). Using western blot, we confirmed high levels of endogenous Bcl2A1 expression in this cell line (Fig. S4) which, after lysis, was found to bond covalently to 2 as detected by western blot (Fig. 7C) . Additionally, live U937 cells were incubated with 2 (and 1) overnight and the extent of covalent conjugation after peptide internalization was evaluated by measuring Bcl2A1 modification in western blot assays (Fig. 7D) . Similar results were observed for HeLa cells overexpressing Bcl2A1 (Fig. S4, S5 ). In summary, a Bim peptide analogue 2, fitted with a helixinducing constraint and an acrylamide electrophile, was demonstrated to bond covalently, irreversibly and specifically to Cys55 within the BH3-binding site of the Bcl2A1 protein. Importantly, 2 (unlike 5 and 6) did not bond covalently and non-specifically to other surface-exposed cysteine residues, either in Bcl2A1 or in three other Bcl2 proteins that did not have a Cys in the PPI interaction site. Compound 2 was also cell permeable and bound to Bcl2A1 in live cells, indicating the promise for covalent helical peptides as long acting inhibitors of intracellular protein-protein interactions. This irreversible binding of inhibitors confers a number of potential advantages over more conventional reversible inhibitors. A covalent inhibitor-protein complex can more effectively prevent competitive binding by other endogenous ligands, anticipated to be especially beneficial in the case of Bcl2A1, which also interacts with others proteins via its BH3 binding site. 24, 28 Irreversible binding inhibitors do not readily dissociate and so their inhibition continues even after the inhibitor leaves the circulation, resulting in less frequent and lower doses of drug to patients. 12 This approach is particularly well suited to peptide-based drugs which are rapidly cleared from the circulation, thereby reducing the chance of non-specific off-target bonding of electrophilic peptides. Thus, a traditional liability of peptides as drugs can be advantageous in the case of electrophilic drugs. Finally, irreversible covalent bonding peptides and peptidomimetics bring the benefit of pharmacological silencing of a protein target, likely for the lifetime of the protein and only terminating with the synthesis of new protein.
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